Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

Yoda, S; Lin, JJ; Lawrence, MS; Burke, BJ; Friboulet, L; Langenbucher, A; Dardaei, L; Prutisto-Chang, K; Dagogo-Jack, I; Timofeevski, S; Hubbeling, H; Gainor, JF; Ferris, LA; Riley, AK; Kattermann, KE; Timonina, D; Heist, RS; Iafrate, AJ; Benes, CH;

Hata, AN (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA.; Shaw, AT (reprint author), Massachusetts Gen Hosp, 32 Fruit St, Boston, MA 02114 USA.

CANCER DISCOVERY, 2018; 8 (6): 714

Abstract

The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The th......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索